Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Salk Institute for Biological Studies
Headquarters: La Jolla, CA, United States of America
Website: http://salk.edu
Year Founded: 1960
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 6, 2021
Finance
Oct. 5 Quick Takes: Nextech leads $78M round for Exo
Plus updates from Zai, Vedanta, Taysha, IpiNovyx
BioCentury | Jan 6, 2021
Emerging Company Profile
Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A
Emerging Company Profile: With tech licensed from Salk, IconOVir is developing tumor-selective oncolytic viruses that can be administered IV
BioCentury | Dec 17, 2020
Emerging Company Profile
Exo: expanding the universe of druggable enzymes
Emerging Company Profile: David Liu’s latest newco launches with $25M to develop small molecules against non-catalytic, non-allosteric enzyme sites
BioCentury | Sep 30, 2020
Distillery Therapeutics
Islet-like organoids expressing PD-L1 for diabetes
DISEASE CATEGORY: Endocrine/metabolic
INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to
INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to
BioCentury | Jun 4, 2019
Tools & Techniques
OHSU's Mitalipov proposes path forward for germline gene editing
BioCentury | May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
BioCentury | Apr 17, 2019
Preclinical News
Salk study unveils LIF's mechanism in form of pancreatic cancer
BioCentury | Jan 18, 2019
Product R&D
Modality moves at Vertex
How Vertex hopes to reach more patients with Arbor's CRISPR tools
Items per page:
1 - 10 of 141